TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03942276

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Consist of performing no exercise training.
Study: NCT06268600

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Modified neck target volume delineation
Description: Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
Study: NCT01812837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
Study: NCT04262869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT04399902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Blanket
Description: Ready-Heat 6-Panel Blanket (Military style, manufactured by Techtrade LLC). The 6-panel military-style blanket (86cm x 152 cm, 1.13kg) warms to 40˚C in approximately 15-20 minutes and maintains this temperature for 10 hours.
Study: NCT03929146

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interscalene Nerve Block
Description: Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
Study: NCT00938873

Intervention type: BEHAVIORAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
Study: NCT00467870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate 1000 mg
Study: NCT03358225

Intervention type: PROCEDURE
Intervention: anterior cervical discectomy and fusion
Description: The patients undergoing anterior cervical discectomy and fusion sugery

Intervention type: PROCEDURE
Intervention: cervical artificial disc replacement
Description: The patients undergoing cervical artificial disc replacement surgery
Study: NCT02046473

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Volumetric Flow in TIPS
Description: Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
Study: NCT00000512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Description: Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: colestipol
Description: Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestipol
Description: Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestipol
Description: Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin
Description: Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for colestipol
Description: Placebo for colestipol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for lovastatin
Description: Placebo for lovastatin
Study: NCT02170701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: Ascending doses (in mg) given twice daily
Study: NCT04229316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zLOCK Facet Stabilization System
Description: zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
Study: NCT01282827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rtACS (verum condition)
Description: Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo stimulation
Description: a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
Study: NCT03536247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initial therapy with papillary balloon dilation
Description: patients will first undergo papillary dilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initial therapy with intraductal lithotripsy
Description: patients will first undergo intraductal laser or electrohydraulic lithrotripsy
Study: NCT04421794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: Neuromuscular Electrical Stimulation (NMES) is a non pharmacological intervention that sends electrical impulses to nerves leading to muscle contraction. The electrical stimulation can increase strength and is often used to re-educate or re-train muscles.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.
Study: NCT03038282

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chromium Chloride
Description: Transdermal chromium chloride 50 to 600 mcg/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Exercise
Description: Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
Study: NCT04343911

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pink Pad ® (Xodus Medical Inc., New Kensington, PA)
Description: a non-sliding foam mattress
Study: NCT03358225

Intervention type: PROCEDURE
Intervention: hybrid surgery
Description: The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
Study: NCT00974168

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cumulative BED ≤ 100
Description: Radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cumulative BED ≤ 130 Gy2
Description: Radiation
Study: NCT01363401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYNR-CS inj
Description: Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No treatment of HYNR-CS inj
Study: NCT01827371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Smallpox Vaccine
Description: Subjects receive two dose regimen of IMVAMUNE® (1x10\^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
Study: NCT00320593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Addition Lenses (PALs)
Description: Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vision Lenses (SVLs)
Description: Single vision lenses
Study: NCT02455583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project AIM (Adult Identity Mentoring)
Description: Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
Study: NCT04779801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy
Description: 16 weeks of Attachment-Based Family Therapy treatment.
Study: NCT00904059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Capsules, Oral, 600 mg, Q12h, Days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Capsules, Oral, 60 mg, Q24h, Days 1-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Capsules, Oral, 200 mg, Q12h, Days 8-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Capsules, Oral, 30 mg, Q24h, Days 8-21
Study: NCT04257240

Intervention type: PROCEDURE
Intervention: selective hepatic vascular exclusion
Description: major hepatectomy with vascular control of blood inflow and outflow of the whole liver

Intervention type: PROCEDURE
Intervention: semielective hepatic vascular exclusion
Description: major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
Study: NCT02191579

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinumtoxinA
Description: 155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Topiramate up to a maximum oral dose of 100 mg/day.
Study: NCT03785483

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivation
Description: 8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation
Description: 8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
Study: NCT03922659

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and Cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and Cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and Cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and Cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation and Cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial magnetic stimulation and Cognitive behavioral therapy
Description: Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
Study: NCT00496106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: 6 telephone counseling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: 6 telephone counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone interview
Description: telephone interview

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone interview
Description: telephone interview
Study: NCT01917903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait-cognitive training
Description: Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identification of at risk variables
Description: Participants will complete walking under three conditions: walking alone for six minutes; standing from a chair, walking 3 meters, turning, and returning to a seated position (TUG); and standing from a chair, walking 3 meters turning and returning to a seated postion while subtracting numbers (TUG Cognitive). Spatiotemporal measures of gait will be collected.
Study: NCT04222322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epitomee Capsule
Description: Arm treatment: Epitomee Capsule combined with moderate intensity lifestyle counseling.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control-Placebo
Description: Arm treatment: Visually matching placebo capsule combined with moderate intensity lifestyle counseling.
Study: NCT01255228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Description: The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet
Description: The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
Study: NCT03501342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Description: Immersive virtual reality training protocol consisted of Football and Guillotine games.
Study: NCT04372771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curves Circuit
Description: The Curves Circuit consists performing 13 hydraulic resistance exercise machines that utilize bidirectional resistance that work all major muscle groups. These are interspersed with floor-based calisthenic exercises designed to maintain an elevated heart rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Watchers
Description: The Weight Watchers program encourages one to increase physical activity.
Study: NCT03268811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
Study: NCT03318575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC
Description: Automated Remote Ischemic Conditioning

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: autoRIC Sham
Description: Automated Remote Ischemic Conditioning Sham
Study: NCT03501342

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Balance Training
Description: Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
Study: NCT04101474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
Study: NCT01944189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food
Description: Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food
Description: Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (\> 5 to \>15 kg receive 1 tablet and 15 to \> 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)
Study: NCT04242381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cold Application
Description: At the beginning of each treatment session, gel ice packs were wrapped in a damp towel and applied to the patients' shoulder joints for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping Application
Description: KT was applied to the deltoid muscle using the inhibition and mechanical correction technique and to the supraspinatus muscle using the inhibition technique (2 sessions with a 5-day interval)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Description: EX treatment was administered for 10 days with 3 sessions/day. A triphasic exercise program was administered to the patients. Before starting the exercise program, the patients were instructed to not perform the movements exceeding 90° overhead. The exercise program was initiated using codman pendulum, passive joint motion range (with a 1-m stick), and posterior capsule stretching exercise. Shoulder wheel, finger ladder, and shoulder strengthening exercise with theraband were added to the exercise programs of patients with full or near total range of motion and pain relief. Exercise was administered twice a week under supervision; however, the patients were advised to exercise at home on the other days with 20 repetitions of each exercise. The patients were followed up via telephone to make sure they were adhering to their exercise programs.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio taping application
Description: Sham-KT was applied in 10 cm I-shaped stripes on the sagittal plane over the acromioclavicular joint without stretching and on the transverse plane distal to the deltoid area. The kinesiotape was applied twice for five days with 2-day intervals
Study: NCT02543086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine Phosphate
Description: Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study